• darkblurbg

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Available positions at Diamyd Medical

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.



 Dates for financial information and other events
February 22 − February 25, 2023
ATTD 2023
February 23, 2023
Erik Penser Bank Temadag
vd Ulf Hannelius presenterar på Erik Penser Banks Temadag: Healthcare. Presentationen sänds live kl. 16:30 CET.
February 27 − March 1, 2023
6th Antigen-Specific Immune Tolerance Summit
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023

Our pipeline for autoimmune diabetes is potentially game changing. Focusing on safe and specific interventions that have the promise to realize the true value of preemptive medicine. Spearheaded by Diamyd®, an antigen-specific immunotherapy for individuals carrying a common risk gene (haplotype DR3-DQ2”), provides us with the opportunity to address up to 40 % of the millions of individuals at risk or diagnosed with autoimmune diabetes in the world.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly report 1 22/23


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research